NCT01660191 (SPARQ) is a Phase 4 clinical trial of Pitavastin 4mg in Hypercholesterolemia, sponsored by University of Kansas Medical Center.

Who is sponsoring NCT01660191?

NCT01660191 is sponsored by University of Kansas Medical Center.

What drugs are being tested in NCT01660191?

Interventions in NCT01660191: Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg.

What condition does NCT01660191 study?

NCT01660191 studies Hypercholesterolemia.

Is NCT01660191 still recruiting?

NCT01660191 is currently completed. Last updated 22 November 2016.

Are results published for NCT01660191?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-11-22 · How we verify

NCT01660191: SPARQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Comparing the Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on Plasma Levels of CoQ10 (SPARQ)

Completed Phase 4 Results posted Last updated 22 November 2016

What this trial tests

Phase 4 trial testing Pitavastin 4mg in Hypercholesterolemia in 134 participants. Completed in 1 October 2013.

Timeline

1 December 2011

Primary endpoint
1 August 2013

1 October 2013

Quick facts

Lead sponsor	University of Kansas Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	134
Start date	1 December 2011
Primary completion	1 August 2013
Estimated completion	1 October 2013
Sites	1 location across United States

Drugs / interventions tested

Pitavastin 4mg — full drug profile →
Atorvastatin 20mg — full drug profile →
Rosuvastatin 5mg — full drug profile →

Conditions studied

Hypercholesterolemia — all drugs for Hypercholesterolemia →

Sponsor

University of Kansas Medical Center

Who can join

Adults 18 to 70, any sex, with Hypercholesterolemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Changes in Plasma CoQ10 Levels
Time frame: Change from Baseline to 12 Weeks
Change in levels will be measured by taking difference between Baseline and Week 12 measures.

Sponsor's own description

The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypercholesterolemia

Currently open trials in the same condition.

NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07295327 — Effect of Two Food Supplements on Lipid Profile in Patients With Mild Hypercholesterolemia · NA · recruiting
NCT06568601 — Pharmacogenomic Informed Statin Prescribing · NA · recruiting
NCT06423365 — A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication. · NA · active not recruiting

Other University of Kansas Medical Center trials

Trials by the same sponsor.

NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01660191 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
Last refreshed: 22 November 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01660191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing